Filing Flows › Evommune (EVMN) › Q3 2025
Evommune (EVMN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Dec 11, 2025
Evommune (EVMN) reported revenue of $10.0M for the third quarter 2025 (Q3 2025). Operating margin was -133.3%, net loss $12.5M (124.8% of revenue).
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.0M | — | — |
| Operating profit | −$13.3M | — | — |
| Net earnings | −$12.5M | — | — |
| Operating cash flow | −$9.6M | — | — |
What changed
Revenue was $10.0M in Q3 2025.
Operating costs exceeded revenue by $13.3M, an operating margin of -133.3%. The quarter ended with a net loss of $12.5M.
Operating cash flow was −$9.6M. Non-cash charges added back $311K of depreciation and amortization and $560K of share-based compensation. Working capital and other items added $2.0M. Capital expenditures of $131K exceeded it, leaving free cash flow of −$9.8M.
Questions
What was Evommune's revenue in the third quarter 2025?
Evommune (EVMN) reported revenue of $10.0M for the third quarter 2025 (Q3 2025).
Was Evommune profitable in the third quarter 2025?
Operating loss was $13.3M (-133.3% of revenue) and net loss $12.5M.
Source: Evommune 10-Q on SEC EDGAR.